How changing your cancer pill's appearance affects your treatment
Part of Cancer clinical trials.
This study looks at how switching from a brand-name cancer pill to a generic version (or between two generics) affects your daily routine, ability to stay on treatment, and overall well-being. If you've been on one of these specific pills for at least 6 months and recently made a switch, the researchers want to learn from your experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are taking one of these oral cancer drugs: capecitabine, imatinib, everolimus, abiraterone, or lenalidomide.
- You have been on your current drug for at least 6 months.
- You recently switched from a brand drug to a generic, or from one generic to another.
- You are not picking up medicine for someone else, and you don't live in a nursing home or facility.
- You have not been in the hospital during the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a set of practical support steps to help people with advanced cancer take their oral (by mouth) treatment medicines correctly. It may help improve adherence and reduce missed doses or appointments.
This British Columbia study looks at how well different cancer treatments work in real life when doctors aren't sure which option is best. You and your doctor would choose a treatment, and researchers will track your results to help others.
This trial tests whether combining regular medication safety checks with electronic tracking of side effects can improve quality of life and help reduce economic burden for people taking cancer pills. It’s for people starting oral cancer therapy and using connected technology to report symptoms.
This trial tests if unused oral cancer pills that were stored at room temperature can be safely given to other patients. If you take a room-temperature oral cancer pill, you may be able to help reduce medication waste.
This trial studies whether a “DROP” support program helps ambulatory people with cancer manage drug-related problems when they start or change oral (by mouth) anticancer treatment. It may help reduce medication mistakes and complications by improving how you handle your regimen at home.
This study looks at how well patients with neuroendocrine tumors handle oral cancer pills and how those pills affect their quality of life. The goal is to improve support and education for people taking these medications at home.
Hear when a new Adherence, Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.